Hesperos
Orlando, US Β· 1 known investors
Hesperos develops "Human-on-a-Chip" organ-on-a-chip platforms, offering custom multi-organ models (up to 5 organ or tissue types) with functional readouts such as gene expression and electrophysiology. The systems provide pre-clinical efficacy and toxicity data on drugs and chemicals for the pharmaceutical, cosmetic, and food industries.
Founders & leadership
Investors Β· 1
Non-dilutive funding Β· 14 SBIR/STTR awards
Federal grants β no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $4.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $216.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $4.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $669.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $450K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $224.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $220.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $454.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts β non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Hesperos do?
- Hesperos develops "Human-on-a-Chip" organ-on-a-chip platforms, offering custom multi-organ models (up to 5 organ or tissue types) with functional readouts such as gene expression and electrophysiology. The systems provide pre-clinical efficacy and toxicity data on drugs and chemicals for the pharmaceutical, cosmetic, and food industries.
- Who founded Hesperos?
- Hesperos was founded by Michael Shuler, James Hickman, Michael L. Shuler, James J. Hickman.
- Who are Hesperos's investors?
- Hesperos's investors include Btomorrow Ventures.
- Where is Hesperos headquartered?
- Hesperos is headquartered in Orlando, US.